Skip to main content

Table 2 Baseline values for primary and secondary outcomes

From: Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

  Ezetimibe add- on group (n = 23) Increased rosuvastatin (n = 20)
ApoB, g/L 1.06 ± 0.24 1.01 ± 0.38
ApoA1, g/L 1.54 ± 0.27 1.51 ± 0.32
ApoB:ApoA1 0.69 ± 0.21 0.72 ± 0.39
TC, mmol/L 5.23 ± 1.06 5.07 ± 0.50
LDL, mmol/L 2.80 ± 0.93 2.55 ± 0.58
HDL, mmol/L 1.21 ± 0.29 1.29 ± 0.40
TC:HDL 4.92 ± 2.25 4.25 ± 1.15
TG, mmol/L 2.55 ± 1.32 3.05 ± 1.52
AIP 0.29 ± 0.33 0.33 ± 0.33
Non-HDL-C, mmol/L 4.04 ± 1.05 3.78 ± 0.69
Glucose, mmol/L 6.54 ± 1.84 6.16 ± 2.22
hsCRP, mg/L 5.6 ± 10.20 2.8 ± 3.37
Creatinine, μmol/L 91 ± 22.50 98 ± 30.51
ALT, U/L 33 ± 13.80 34 ± 12.70
AST, U/L 29 ± 11.0 30 ± 11.40
CK, U/L 142 ± 100.0 177 ± 85.22
  1. Data are given as mean (±SD)
  2. apoB, apolipoprotein B; apoA1,apolipoprotein A1;TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides; AIP, atherogenic index of plasma; FBG, fasting blood glucose; hsCRP, high-sensitivity C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatine kinase